Mesothelin-targeted agents in clinical trials and in preclinical development

Molecular Cancer Therapeutics

Volumn 11, Issue 3, 2012, Pages 517-525

  Kelly, Ronan J ^a   Sharon, Elad ^a   Pastan, Ira ^a   Hassan, Raffit ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; AMATUXIMAB; ANTINEOPLASTIC AGENT; BAY 949343; BEVACIZUMAB; CA 125 ANTIGEN; CANCER VACCINE; CARBOPLATIN; CISPLATIN; CONDITIONALLY REPLICATING ADENOVIRUS; CRS 207; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMMUNOTOXIN; IMMUNOTOXIN SS1P; MDX 1204; MESOTHELIN; PACLITAXEL; PEMETREXED; PLACEBO; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ADVANCED CANCER; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER IMMUNIZATION; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTINUOUS INFUSION; DELAYED HYPERSENSITIVITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG HALF LIFE; DRUG POTENTIATION; DRUG TARGETING; EARLY TERMINATION OF CLINICAL TRIAL; EDEMA; FATIGUE; HUMAN; HYPERTRANSAMINASEMIA; HYPOALBUMINEMIA; LUNG ADENOCARCINOMA; LUNG CANCER; MESOTHELIOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SERUM SICKNESS; SOLID TUMOR; TREATMENT RESPONSE; URTICARIA; VASCULAR DISEASE; VASCULAR LEAK SYNDROME;

ANIMALS; ANTIBODIES, MONOCLONAL; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; GPI-LINKED PROTEINS; HUMANS; IMMUNOTOXINS; NEOPLASMS;

EID: 84859379903     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0454     Document Type: Review

References (56)

1. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A 1996;93:136-40. (Pubitemid 26041483)
2. Chang K, Pastan I, Willingham MC. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 1992;50:373-81.
3. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res 2004;10:3937-42. (Pubitemid 38812466)
4. Yamaguchi N, Hattori K, Oh-eda M, Kojima T, Imai N, Ochi N. A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. J Biol Chem 1994;269:805-8. (Pubitemid 24032445)
5. Ordóñez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 2003;27:1418-28. (Pubitemid 37315193)
6. Ordóñez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 2003;16:192-7. (Pubitemid 36337423)
7. Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 2001;7:3862-8. (Pubitemid 34044602)
8. Hassan R, Kreitman RJ, Pastan I, Willingham MC. Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol 2005;13:243-7. (Pubitemid 41209017)
9. Miettinen M, Sarlomo-Rikala M. Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am J Surg Pathol 2003;27:150-8. (Pubitemid 36152223)
10. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer 2008;44:46-53. (Pubitemid 350262830)
11. Bera TK, Pastan I. Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol 2000;20:2902-6. (Pubitemid 30183509)
12. Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 2004;279:9190-8. (Pubitemid 38295982)
13. Gubbels JA, Belisle J, Onda M, Rancourt C, Migneault M, Ho M, et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer 2006;5:50-65.
14. Li M, Bharadwaj U, Zhang R, Zhang S, Mu H, Fisher WE, et al. Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol Cancer Ther 2008;7:286-96. (Pubitemid 351302523)
15. Wang T, Kajino K, Abe M, Tan K, Maruo M, Sun G, et al. Suppression of cell death by the secretory form of N-terminal ERC/mesothelin. Int J Mol Med 2010;26:185-91.
16. Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 2007;13:5144-9. (Pubitemid 47502082)
17. Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res 2009;15:5274-9.
18. Hassan R, Sharon E, Schuler B, Mallory Y, Zhang J, Ling A, et al. Antitumor activity of SS1P with pemetrexed and cisplatin for front-line treatment of pleural mesothelioma and utility of serum mesothelin as a marker of tumor response. J Clin Oncol 29:15s, 2011 (suppl; abstr 7026).
19. Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, et al. Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res 2010;16:6132-8.
20. ClinicalTrials.gov [homepage on the Internet]. Identifier: NCT00570713.
21. ClinicalTrials.gov [homepage on the Internet]. Identifier: NCT00738582.
22. Le DT, Nir-Paz R, Hamp J, Mathur S, Neumanitis J, Steiman D, et al. Results of phase I studies testing twolive-attenuated Listeria vaccines, ANZ-100 and CrS-207, for the treatment of cancer. AACR Conference, Tumor Immunology: Basic and Clinical Advances, Nov 30-Dec 3, 2010, Miami Beach, FL (Abstract).
23. ClinicalTrials.gov [homepage on the Internet]. Identifier: NCT01417000.
24. ClinicalTrials.gov [homepage on the Internet]. Identifier: NCT01355965.
25. ClinicalTrials.gov [homepage on the Internet]. Identifier: NCT01439152.
26. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin treatment of cancer. Annu Rev Med 2007;58:221-37. (Pubitemid 46706511)
27. Chowdhury PS, Viner JL, Beers R, Pastan I. Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc Natl Acad Sci U S A 1998;95:669-74. (Pubitemid 28083801)
28. Chowdhury PS, Pastan I. Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat Biotechnol 1999;17:568-72. (Pubitemid 29262920)
29. Hassan R, Lerner MR, Benbrook D, Lightfoot SA, Brackett DJ, Wang QC, et al. Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. Clin Cancer Res 2002;8:3520-6. (Pubitemid 35340730)
30. Li Q, Verschraegen CF, Mendoza J, Hassan R. Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas. Anticancer Res 2004;24[3a]:1327-35. (Pubitemid 38954646)
31. Zhang Y, Xiang L, Hassan R, Paik CH, Carrasquillo JA, Jang BS, et al. Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice. Clin Cancer Res 2006;12:4695-701. (Pubitemid 44297823)
32. Hassan R, Broaddus VC, Wilson S, Liewehr DJ, Zhang J. Antimesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts. Clin Cancer Res 2007;13:7166-71. (Pubitemid 350276903)
33. Zhang Y, Xiang L, Hassan R, Pastan I. Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors. Proc Natl Acad Sci U S A 2007;104:17099-104. (Pubitemid 350210998)
34. Hassan R, Williams-Gould J, Watson T, Pai-Scherf L, Pastan I. Pre-treatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1. Clin Cancer Res 2004;10:16-8. (Pubitemid 38114156)
35. Mossoba ME, Onda M, Taylor J, Massey PR, Treadwell S, Sharon E, et al. Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts. Clin Cancer Res 2011;17:3697-705.
36. ClinicalTrials.gov [homepage on the Internet]. Identifier: NCT01362790.
37. Hassan R, Ebel W, Routhier EL, Patel R, Kline JB, Zhang J, et al. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun 2007;7:20.
38. Hassan R, Schweizer C, Lu KF, Schuler B, Remaley AT, Weil SC, et al. Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy. Lung Cancer 2010;68:455-9.
39. Brockstedt DG, Giedlin MA, Leong ML, Bahjat KS, Gao Y, Luckett W, et al. Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci U S A 2004;101:13832-7. (Pubitemid 39298493)
40. Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol 2006;90:51-81. (Pubitemid 43765799)
41. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126-9. (Pubitemid 44547756)
42. Ramos CA, Dotti G. Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther 2011;11:855-73.
43. Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008;112:2261-71.
44. Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A 2009;106:3360-5.
45. Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res 2010;70:9053-61.
46. Rao C, Huber M, Vemuri K, Zhang Q, Chen B, Phillips J, et al.Efficacy and toxicity of an anti-mesothelin antibody drug conjugate [abstract]. In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22, Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 3235.
47. Golfier S, Kahnert A, Heisler I, Kopitz C, Berhirster K, Stelte-Ludwig B, et al.Identification of BAY 94-9343, a mesothelin antibody-drug conjugate (ADC): characterization and anti-tumor activity in mesothelin-positive preclinical tumor models. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR: 2011. Abstract nr 1754.
48. Ho M, Hassan R, Zhang J, Wang QC, Onda M, Bera T, et al. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res 2005;11:3814-20. (Pubitemid 40685601)
49. Thomas AM, Santarsiero LM, Lutz ER, Armstrong TD, Chen YC, Huang LQ, et al. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med 2004;200:297-306. (Pubitemid 39031249)
50. Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B, et al. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res 2008;14:1455-63. (Pubitemid 351413929)
51. Yokokawa J, Palena C, Arlen P, Hassan R, Ho M, Pastan I, et al. Identification of novel human CTL epitopes and their agonist epitopes of mesothelin. Clin Cancer Res 2005;11:6342-51. (Pubitemid 41262966)
52. Chang CL, Wu TC, Hung CF. Control of human mesothelin-expressing tumors by DNA vaccines. Gene Ther 2007;14:1189-98.
53. Miyazawa M, Iwahashi M, Ojima T, Katsuda M, Nakamura M, Nakamori M, et al. Dendritic cells adenovirally-transduced with full-length mesothelin cDNA elicit mesothelin-specific cytotoxicity against pancreatic cancer cell lines in vitro. Cancer Lett 2011;305:32-9.
54. Wang B, Kuroiwa JM, He LZ, Charalambous A, Keler T, Steinman RM. The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells. Ann N Y Acad Sci 2009;1174:6-17.
55. Breidenbach M, Rein DT, Everts M, Glasgow JN, Wang M, Passineau MJ, et al. Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy. Gene Ther 2005;12:187-93. (Pubitemid 40185922)
56. Tsuruta Y, Pereboeva L, Breidenbach M, Rein DT, Wang M, Alvarez RD, et al. A fiber-modified mesothelin promoter-based conditionally replicating adenovirus for treatment of ovarian cancer. Clin Cancer Res 2008;14:3582-8.